dChan
Anonymous ID: db9a36 May 19, 2020, 6:52 p.m. No.9246525   🗄️.is 🔗kun   >>6540 >>6542 >>6548 >>6571 >>6577 >>6591 >>6603 >>6604 >>6609 >>6623 >>6631 >>6717 >>6741 >>6751 >>6824 >>6827

POTENTIAL NOTABLE THEORY

For Anon's consideration

 

WHY do the [D]'s and the media have such a hatred of HCQ? I think I have the answer. (Full disclosure I am the author of a pre-print medical paper on the hemoprotein etiology of COVID-19)

Essentially COVID-19 is a blood disease that manifests in the lungs (via pneumocyte desquamation.) It does damages by stripping iron from its 'cage' (porphyrin) in your red blood cells. This iron leads to iron overload, which is why the disease damages both lungs simultaneously in all patients…. I could go on if anons are interested in that BUT

Why HCQ? It is an anti-malarial (quinoline derivative) that prevents the iron from being removed from its porphyrin cage, which stops the disease progression. And why zinc? Well zinc inhibits the replication of 'rogue' DNA and RNA– the kind you find in SARS-coronavirus-2…. and viruses in general… and cancerous cells…. Do you see where I am going with this??

HCQ biocrystallizes 'heme' iron and this is toxic to malarial larvae- hence its use in fighting malaria

BUT combined with ZINC supplementation, the HCQ allows the zinc to enter the macrophages and red blood cells that are infected with the virus- stopping the virus from reproducing— hence the miraculous results of HCQ, but only when combined with ZINC.

BUT WAIT THERES MORE! What if… What if this combination inhibited ALL viral replication? Herpes, Epstein Barr, FLU! What if it inhibited cancerous cells (with their mutated genetic code) from replicating themselves?

Well big pharma wouldn't like that! I mean, how can you make billions off treating viral infections if the cure costs 5$ for a weeks dosage?

Anonymous ID: db9a36 May 19, 2020, 7:01 p.m. No.9246603   🗄️.is 🔗kun   >>6631 >>6694 >>6827

>>9246525

>>9246566

 

1) Fan C, Li K, Ding Y, Lu W, & Wang J. (2020) ACE2 expression in kidney and testis may cause kidney and testis damage after 2019‐nCoV infection. PRE-PRINT available at https://www.medrxiv.org/content/10.1101/2020.02.12.20022418v1.full.pdf+html

(2) Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., et al. (2020) Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA, April 6, 2020. E-publication ahead of print available at: https://www.ncbi.nlm.nih.gov/pubmed/32250385

(3) Harrison-Findik, D. D. (2010). Gender-related variations in iron metabolism and liver diseases. WORLD JOURNAL OF HEPATOLOGY, 2(8): 302–310. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999297/

(4) Kohgo, Y., Ikuta, K., Ohtake, T., Torimoto, Y., & Kato, J. (2008) Body iron metabolism and pathophysiology of iron overload. INTERNATIONAL JOURNAL OF HEMATOLOGY. 88(1): 7–15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2516548/

(5) Li, T., Lu, H. & Zhang, W. (2020) Clinical observation and management of COVID-19 patients. EMERGING MICROBES AND INFECTIONS, 9(1): P687–690. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103696/

(6) Liu, W. & Li H.(2020) PRE-PRINT available at: https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173

(7) Schaer, Christian A., Laczko, E., Schoedon, G. Schaer, D. J., & Vallelian, F. (2013) OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, VOLUME 2013 https://www.hindawi.com/journals/omcl/2013/870472/

(8) Wang, Y., Wang Y., Chen, Y, & Qin, Q. (2020) Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. JOURNAL OF MEDICAL VIROLOGY, March 5, 2020. Pre-publication available at: https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25748

(9) Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C. et al. (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. THE LANCET, VOLUME 8, ISSUE 4, P420-422. https://www.thelancet.com/journals/lancet/article/PIIS2213-2600(20)30076-X/fulltext

(10) Zhang, C., Shi, L., & Wang, F. (2020) Liver injury in COVID-19: management and challenges. THE LANCE, VOLUME 5, ISSUE 5, P428-430. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30057-1/fulltext

(11) Zhou, M., Zhang, X., & Qu, J. (2020) Coronavirus disease 2019 (COVID-19): a clinical update. FRONTIERS OF MEDICINE, APRIL 2, 2020. https://link.springer.com/content/pdf/10.1007/s11684-020-0767-8.pdf